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Abstract
Background: In this study we describe the clinical and molecular characteristics of an outbreak due to
carbapenem-resistant Klebsiella pneumoniae (CR-KP) producing CTX-M-15 and OXA-48 carbapenemase. Isogenic
strains, carbapenem-susceptible K. pneumoniae (CS-KP) producing CTX-M-15, were also involved in the outbreak.
Results: From October 2010 to December 2012 a total of 62 CR-KP and 23 CS-KP were isolated from clinical
samples of 42 patients (22 had resistant isolates, 14 had susceptible isolates, and 6 had both CR and CS isolates).
All patients had underlying diseases and 17 of them (14 patients with CR-KP and 3 with CS-KP) had received
carbapenems previously. The range of carbapenem MICs for total isolates were: imipenem: 2 to >32 μg/ml
vs. <2 μg/ml; meropenem: 4 to >32 μg/ml vs. <2 μg/ml; and ertapenem: 8 to >32 μg/ml vs. <2 μg/ml. All the
isolates were also resistant to gentamicin, ciprofloxacin, and cotrimoxazole. Both types of isolates shared a
common PFGE pattern associated with the multilocus sequence type 101 (ST101). The blaCTX-M-15 gene was
detected in all the isolates, whereas the blaOXA-48 gene was only detected in CR-KP isolates on a 70 kb plasmid.
Conclusions: The clonal spread of K. pneumoniae ST101 expressing the OXA-48 and CTX-M-15 beta-lactamases
was the cause of an outbreak of CR-KP infections. CTX-M-15-producing isolates lacking the blaOXA-48 gene
coexisted during the outbreak.
Background
Nosocomial outbreaks due to multidrug-resistant enter-
obacteria have become a serious problem worldwide,
especially due to the spread of extended spectrum beta-
lactamase (ESBL)-producing strains and to the posterior
emergence of carbapenemases [1]. In Europe, carbapenem
resistance among K. pneumoniae isolates is related to the
presence of multidrug-resistant isolates producing beta-
lactamases belonging to the KPC, VIM, or OXA-48 fam-
ilies, making the treatment of infections difficult due to
these microorganisms [1].
In Spain, carbapenem-resistant K. pneumoniae (CR-KP)
strains have been described sporadically due to production
of VIM-type enzymes and, more recently, OXA-48 [2, 3].
In addition, after whole genome sequencing of a ST101
OXA-48-producing K. pneumoniae, revealed that the
blaOXA-48 gene was recently found in IncL/M plasmids
previously described [4, 5].
In our hospital, a tertiary teaching hospital in Spain, an
active surveillance program for ESBL- and carbapenemase-
producing enterobacteria has been ongoing since the 1990s
[6]. In this study we describe the clinical and molecular
epidemiology of a nosocomial outbreak due to a K. pneu-
moniae clone producing CTX-M-15 and OXA-48. Interest-
ingly, isogenic K. pneumoniae isolates producing the
CTX-M-15 enzyme but lacking the blaOXA-48 gene
were also detected during the same period of time.
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Methods
Ethics statement
This study was approved by the Clinical Research Ethics
Committee of Bellvitge University Hospital (PR334/14).
Written informed consent was not necessary for this
retrospective study as it was part of our standard micro-
biological routine. Patient data were anonymized for
the purposes of this analysis, and all confidential pa-
tient information was protected in accordance with
Spanish law.
Hospital setting
The study was carried out in the Hospital Universitari
de Bellvitge, a 900-bed university teaching hospital for
adult patients in Barcelona (Spain) that provides medical
and surgical care in all areas except pediatrics, obstetrics,
and burns. The hospital serves an area of 600,000 inhab-
itants and admits an average of 24,000 patients per year.
Bacterial isolates and clinical data collection
This retrospective study was initially designed to identify
CR-KP isolates, although the results obtained drew our
attention to the importance of CS-KP present during the
same period. Computerized clinical charts of patients
with CR-KP or their clonally related CS-KP isolates were
retrospectively reviewed in order to collect clinically
relevant data: demographics, clinical features, treat-
ments, and outcomes. From October 2010 to December
2012, all CR-KP and CS-KP isolates were selected from
clinical samples.
The clinical relevance assessment was determined in
accordance with the CDC/NHSN surveillance definition
of health care-associated infection in patients with sam-
ples from any body site positive for CR-KP, but without
related signs or symptoms of infection. In those cases,
patients were considered to be colonized [7].
Antimicrobial susceptibility testing and molecular typing
Antimicrobial susceptibility was tested by microdilution
using the commercial method MicroScan® (Siemens, USA).
The presence of carbapenemases was tested by the
double-disk synergy test between disks containing car-
bapenems and disks with amoxicillin/clavulanic acid,
EDTA, and boronic acid.
The MICs of different antimicrobials were interpreted
using the new EUCAST breakpoints valid from 2015
(http://www.eucast.org/clinical_breakpoints/): imipenem
(IPM): susceptible, MIC ≤ 2 μg/ml and resistant, MIC >
8 μg/ml; meropenem (MEM): susceptible, MIC ≤ 2 μg/
ml and resistant, MIC > 8 μg/ml; ertapenem: susceptible,
MIC ≤ 0.5 μg/ml and resistant, MIC > 1 μg/ml; gentami-
cin (GEN): susceptible, MIC ≤ 2 μg/ml and resistant, MIC >
4 μg/ml; amikacin (AMK): susceptible MIC ≤8 μg/ml and
resistant, MIC > 16 μg/ml; trimethoprim-sulfamethoxazole
(SXT): susceptible, MIC ≤ 2 μg/ml and resistant, MIC
> 4 μg/ml; and ciprofloxacin (CIP): susceptible, MIC
≤ 0.5 μg/ml and resistant, MIC > 1 μg/ml.
The genetic relatedness of all multidrug-resistant K.
pneumoniae isolates was tested by pulsed field gel elec-
trophoresis (PFGE) of chromosomal DNA after restric-
tion with XbaI. Band patterns were analyzed by visual
inspection following the criteria described by Tenover
et al. [8]. Strains differing in 3 or less bands were con-
sidered subtypes. Isolates from the different PFGE sub-
types were selected for multi-locus sequence typing
(MLST). MLST was performed as described on the MLST
website of the Institute Pasteur: http://bigsdb.web.pas
teur.fr/klebsiella/klebsiella.html. The allele number and se-
quence type (ST) were assigned using this MLST website.
Characterization of the multidrug-resistance pattern
Beta-lactamase characterization
A multiplex PCR assay described by Fang et al., which
includes detection of blaOXA, blaCTX-M, blaTEM, and
blaSHV, was used for beta-lactamase detection in all K.
pneumoniae isolates [9]. For CTX-M enzymes a second
PCR was performed to discriminate between blaCTX-M-9
group, blaCTX-M-10 group, and blaCTX-M-1 group [10].
Other carbapenemase genes were detected by PCR
amplification following previously published proce-
dures: class A carbapenemases (KPC, IMI, NMC, GES)
[11], metallo-beta-lactamases (IMP-1, IMP-2, VIM-1,
VIM-2, GIM, SIM, SPM) [11], and the oxacillinase
(OXA-48) [12]. PCR products were purified and se-
quenced in both strands using the amplification
primers at Macrogen Inc. (Korea).
Plasmid analysis
Plasmid analysis and location of the genetic support of
the OXA-48 carbapenemase were performed. Plasmid
DNA from two CR-KP and two CS-KP clinical isolates
was extracted using the GeneJET plasmid miniprep kit
(Thermo Scientific), and was analyzed by electrophoresis
on 0.7 % agarose gels. Plasmid size was determined by
comparison with those from the standard strains
Escherichia coli NCTC 50193 (CECT678) and NCTC
59192 (CECT679), ranging in size from 163.3 to 2 kb.
The K. pneumoniae 7680 strain, containing a plasmid
with the blaOXA-48 gene, was used as a positive control.
Escherichia coli strains CECT678 and CECT679 were
used as molecular weight markers (http://www.strai
ninfo.net). CECT678 contains natural plasmids of
54.38 kb, 7.30 kb, 5.56 kb, 5.14 kb, 3.98 kb, 3.08 kb,
2.71 kb, and 2.06 kb; CECT679 contains plasmids of
154 kb, 66.2 kb, 37.6 kb, and 7.4 kb [13]. To locate the
blaOXA-48 gene, gels with plasmid DNA were trans-
ferred to a nylon membrane by the Southern technique
and hybridized with a PCR-generated OXA-48 probe,
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labeled with dUTP-digoxigenin. Detection of hybrids
was done using an antidigoxigenin antibody coupled to
alkaline phosphatase following the manufacturer’s indi-
cations (Roche Diagnostics).
Results
Outbreak description
The first isolation of the carbapenem-resistant Klebsiella
pneumoniae (CR-KP) occurred in late October 2010, in
a patient who developed a surgical site infection (intra-
abdominal abscess) due to a complication during surgery
for colon cancer. A total of 62 CR-KP isolates were ob-
tained from 28 hospitalized patients from October 2010
to December 2012. The outbreak was initially restricted
to the Digestive Surgery Unit but it was subsequently
spread throughout the Intensive Care Unit (ICU). A
total of 42.85 % of infected patients were detected in
the period January-April 2011 (maximum peak of inci-
dence) (Fig. 1).
During a routine control of ESBL-producing K. pneu-
moniae by molecular typing (PFGE) we also detected
some carbapenem-susceptible K. pneumoniae (CS-KP)
isolates, all of them with the same PFGE pattern as the
CR-KP epidemic strain (denominated PFGE-1). The
ESBL-CS-KP strains were isolated from February 2011
to May 2012 in 23 clinical samples from 14 patients,
whereas the non-ESBL-CS-KP isolates were mainly
detected between July and November 2011 (50 % of
the isolates identified in 7 patients). However, their
carbapenem-resistant counterparts were present until
the end of the study period. Thereafter, a gradual de-
crease in new cases of CR-KP with the same PFGE
pattern was detected in relation to general control
measures implemented during the third trimester of
2011.
Throughout the whole period, six patients had CR-KP
and CS-KP isolates in different clinical samples (n = 26
isolates). In four of these patients the resistant CR-KP
isolates preceded the susceptible CS-KP one. In Fig. 1 a
single isolate is represented for each patient; patients
with both CR-KP and CS-KP isolates are represented
just once as presenting the CR-KP isolate.
The clinical timelines for the 28 patients with isolation
of CR-KP (22 CR-KP and 6 with both isolate types) are
shown in Fig. 2. Fourteen of the patients with CR-KP
isolates had previously received carbapenems (marked
with a star). Most patients with CR-KP isolates were ad-
mitted to ICU and surgical wards.
Clinical characteristics, therapy, and outcomes
Table 1 shows the clinical characteristics and demographics
of patients with clinical samples yielding CR-KP or CS-KP.
Patients with both strains (CR- and CS-KP) were analyzed
only in the group of CR-KP isolates. Overall, there were no
differences in terms of demographics, site of isolation, or
comorbid conditions.
Prior antibiotic therapy was more frequent among
patients with CR-KP (28/28 vs. 11/14; p = 0.032) and
especially involved carbapenems, although the difference
in this latter respect did not reach statistical significance
(14/28 vs. 3/14; p = 0.102).
Twenty out of 28 patients with clinical CR-KP samples
were considered to have an infection due to this micro-
organism. Of these, 19 received antibiotic treatment (as
well as other adjunctive therapies in some cases), which
in 17 cases was considered appropriate according to the
susceptibility test: tigecycline (n = 7, one of them in
combination with AMK), carbapenems other than erta-
penem (n = 4, in which cases the bacteria exhibited an
intermediate sensitivity to the carbapenem selected, one
Fig. 1 Detection of clinical samples with ESBL-producing K. pneumoniae and non-ESBL-producing K. pneumoniae. Black bars represent CS-KP
ESBL strains belonging to the PFGE-1 pattern and gray bars represent non-PFGE-1 pattern ESBL K. pneumoniae. Black line represents patients
with CR-KP non-ESBL strains harboring the blaOXA-48 gene that belonged to the PFGE-1 pattern
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of them in combination with AMK), colistin (n = 4),
AMK (n = 1), and fosfomycin (FOF) (n = 1). Twelve of
these 17 patients (70.58 %) recovered after treatment,
while the other five died (three of them probably related
to the CR-KP infection). The remaining three patients
did not receive appropriate antimicrobial therapy: one
patient treated with amoxicillin/clavulanic acid (AMC)
survived, another treated with piperacillin/tazobactam
(TZP) died due to a septic shock related to CR-KP, and
the third did not receive treatment and died.
Nine of 14 patients with clinical samples yielding CS-
KP were considered infected. Of these, eight were
treated with carbapenems (one of them in combination
with AMK) and one with tigecycline. Only one patient
treated with IPM died (due to a urinary sepsis), although
CS-KP did not appear to be the primary cause of death.
There was a significant difference in the use of carba-
penems as antibiotic treatment among infected patients
(3/20 vs. 7/9; p = 0.002). No other statistical difference
was detected among CR-KP and CS-KP patients.
Phenotypic and molecular characterization of the isolates
By disk diffusion all CR-KP isolates showed synergy be-
tween AMC and carbapenems, and the Hodge test was
positive, suggesting carbapenemase activity. By contrast,
CS-KP isolates did not present these phenotypic charac-
teristics. CR- and CS-KP isolates were multidrug resistant.
Table 2 shows the range of MICs of different anti-
microbial agents. IPM MICs of CR-KP isolates ranged
from 2 to >32 μg/ml, MEM MICs from 4 to >32 μg/ml,
and ertapenem MICs from 8 to >32 μg/ml. All iso-
lates with MICs of IPM >32 μg/ml were resistant to
cefoxitin (FOX) (MIC >16 μg/ml). Using current
EUCAST breakpoints, all the isolates had ertapenem
MICs in the resistant range (breakpoint for resistance
MIC >1 μg/ml).
A common PFGE pattern was observed in all CR-KP
and CS-KP isolates that was different to those observed
in other ESBL-producing K. pneumoniae isolates col-
lected in the same period (data not shown). Among
CR-KP isolates there was a single PFGE pattern type
designated PFGE-1, whereas CS-KP isolates showed
the same PFGE-1 pattern with six different subtypes
(Table 2). Ten representative isolates from the differ-
ent subtypes (4 CR-KP and 6 CS-KP isolates) were
typed by MLST and showed an identical allelic profile:
gapA (allele number 2), infB (allele number 6), mdh
(allele number 1), pgi (allele number 5), phoE (allele
number 4), rpoB (allele number 1), and tonB (allele
number 6), associated with ST101.
The blaCTX-M gene was detected by PCR in all CR-KP
and CS-KP isolates, whereas the blaOXA-48 gene was
only present in CR-KP isolates. After sequencing, the
beta-lactamases were identified as CTX-M-15 and OXA-
Fig. 2 Clinical features of the 28 patients with carbapenem-resistant K. pneumoniae isolates. Each line represents one patient from his/her hospital
admission until discharge or death. Squares and circles only represent time units (one week) in hospital with no samples obtained on those days.
Previous carbapenem treatment is marked with a star drawn on the left of each patient line. The moment of infection or colonization is indicated
with a diamond shape
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48. The remaining carbapenemase genes were not de-
tected by PCR.
Plasmid analysis
Southern blot hybridization analysis of plasmid DNA
from two resistant and two susceptible clinical isolates
identified a plasmid of approximately 70 kb in the CR-
KP isolates. This plasmid had the same size as the
control strain (K. pneumoniae 7680). Southern blot
hybridization with the OXA-48 probe demonstrated
the presence of the blaOXA-48 gene within this plasmid
(Fig. 3). Plasmid analysis of representative carbapenem
resistant and carbapenem susceptible clinical strains
(2 of each) revealed the presence of 6 and 5 plasmids
respectively, ranging in size from 1.9 Kb to 70 kb.
Plasmid profile was identical in both CS-KP and CR-
KP strains except for the presence of an extra 70 kb
structure in the CR-KP isolates.
Discussion
In the present study the carbapenem MICs of the CR-KP
isolates producing OXA-48 had a broad range. Following
the EUCAST criteria, CR-KP isolates had carbapenem
MICs in the intermediate or resistant range, with the
Table 1 Epidemiological and clinical data of patients with CR-KP and CS-KP isolates
CR-KP CS-KP p-value
N = 28 N = 14
Mean age (SD) 62.93 (+/- 14.491) 69.62 (+/- 16.717) 0.186
Male sex 18 (64.3 %) 7 (50 %) 0.508
Site of isolation
Urine 10 (35.7 %) 9 (64.3 %) 0.107
Blood culture 6 (21.4 %) 2 (14.3 %) 0.697
Surgical wound 4 (14.3 %) 1 (7.1 %) 0.650
Abdominal samples 3 (10.7 %) 0 0.539
Respiratory samples 4 (14.3 %) 1 (7.1 %) 0.643
Others 1 (3.6 %) 1 (7.1 %) 1
Length of stay before acquisition (SD) 28.43 (+/- 31.319) 20.14 (+/- 31.705) 0.430
Overall mortality (related CR- or CS-KP)a 35 % [7/20] 11.11 % [1/9] 0.371 (0.280)
(20 % [4/20]) (0)
ICU acquisition 9 (32.1 %) 0 0.019*
Previous antibiotic therapy (treatment)
Penicillins/Betalactamase Inhibitor 8 (28.6 %) 2 (14.3 %) 0.451
Carbapenems 14 (50 %) 3 (21.4 %) 0.102
Third generation cephalosporins/Monobactams 2 (7.1 %) 1 (7.1 %) 1
Fluoroquinolones 4 (14.3 %) 3 (21.4 %) 0.668
Trimethoprim-sulfamethoxazole 0 2 (14.3 %) 0.106
None 0 3 (21.4 %) 0.032*
Treatment
Penicillins/Betalactamase Inhibitor 1 (3.6 %) 0 1
Carbapenems 3 (10.7 %) 7 (50 %) 0.008*
Carbapenems + Amikacin 1 (3.6 %) 1 (7.1 %) 1
Tigecycline 6 (21.4 %) 1 (7.1 %) 0.392
Tigecycline + Amikacin 1 (3.6 %) 0 1
Aminoglycosides 1 (3.6 %) 0 1
Colistin 4 (14.3 %) 0 0.283
Fosfomycin 1 (3.6 %) 0 1
None 1 (3.6 %) 0 1
*p < 0.05 being considered significant
aPatients with non-significant isolation of CR-KP or CS-KP, considered colonized, were excluded from the mortality analysis
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exception of seven isolates which had IPM MICs of 2 μg/
ml. In addition, all OXA-48-producing isolates had ertape-
nem MICs ranging from 4 to >32 μg/ml, which is consid-
ered resistant. It is known that ertapenem MICs are
easily altered in carbapenemase-producing isolates, and
this is reflected in our observations here. Therefore,
ertapenem resistance could be a good microbiological
alert for detecting isolates with the presence of these
enzymes. It should be noted that isolates with higher
carbapenems MICs (for instance, IPM >32 μg/ml) were
also FOX-resistant, suggesting that other mechanisms,
such as the loss of porins could be involved in these
resistant strains, as previously described [2, 11]. Other
authors have suggested the efficacy of temocillin for
OXA-48 producers screening and quickly recognition.
In our experience (data not shown), although both iso-
lates were temocilin-resistant, OXA-48 producers had
no inhibition zone while a small zone was observed in
the other strains [14]. Therapeutic options in patients
infected by CR-KP are very limited. Indeed, beta-lactam
resistance mediated by OXA-family beta-lactamases is
known to be poorly inhibited by beta-lactamase inhibi-
tors [15]. Therefore, and based on our experience,
combinations of a beta-lactam plus beta-lactamase
inhibitor should not be used for the treatment of CR-
KP-producing OXA-48 enzymes. Other beta-lactam
antibiotics, such as aztreonam and expanded spectrum
cephalosporins, are theoretically useful in infections
caused by OXA-48-producing clones, although the
association of a CTX-M-15 in this outbreak precluded
their use in our patients [16].
According to recent reports, there is limited evidence
to support the use of tigecycline, which appears to show
low effectiveness for treating CR-KP infections [15]. In
our experience this antibiotic was effective (5 of 7 pa-
tients cured), although in three cases a surgical drainage
of the abscess was also needed. Two patients treated
with tigecycline died, although in one case the death
was not related to the infection, while the other death
was due to a bacteremic septic shock. Therapeutic
options in patients infected by CR-KP are, therefore, very
limited, and clinicians must often resort to old antibiotics
with a non-negligible toxicity, as is the case of colistin,
which was successfully used in four patients in our
series [16, 17].
The use of carbapenems to treat OXA-48-producing
enterobacteria with MICs of carbapenems in the
Table 2 Characteristics of CR-KP and CS-KP isolates
CR-KP CS-KP
Number of different
patients
28 14
Period of isolation Oct 2010- Dec 2012 Dec 2010- May 2012
Betalactamase
production
CTX-M-15 and OXA-48 CTX-M-15
PFGE profile and
subtypes
PFGE-1 PFGE-1 and 6
subtypes
MLST 101 101
Antimicrobial
susceptibility
Antimicrobial MIC range (mg/L) MIC range (mg/L)
Gentamycin >8 >8
Amikacin <8 <8
Cotrimoxazole >4 >4
Ciprofloxacin >2 >2
Imipenem 2 / >32 <2
Meropenem 4 / >32 <2
Ertapenem 8 / >32 <8
a) b) 
1     2     3     4    5     6    7    8 1     2     3      4     5     6     7    8
66.2kb 
 ~70kb 
Fig. 3 Plasmid profile of CR-KP and CS-KP isolates. a Agarose gel electrophoresis of K. pneumoniae plasmid DNA, and b Southern blot
hybridization using a blaOXA-48 specific probe. Arrows show the presence of a ~70 kb OXA-48-containing plasmid in the CR-KP samples. Lane 1: CECT
678 (54.38 kb, 7.30 kb, 5.56 kb, 5.14 kb, 3.98 kb, 3.08 kb, 2.71 kb, and 2.06 kb plasmids); Lane 2: CECT 679 (154 kb, 66.2 kb, 37.6 kb, and 7.4 kb plasmids);
and Lane 7: Low range ladder as controls. Lanes 3 and 5: CR-KP clinical isolates. Lanes 4 and 6: CS-KP clinical isolates. Lane 8: Positive control
K. pneumoniae strain (K. pneumoniae 7680)
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intermediate range is a controversial issue. In recent out-
breaks, sporadic cases of reported treatment have not
shown good results [18], although the volume of informa-
tion is very limited. In the present study, four patients
with CR-KP infections received carbapenems (cases in
which the bacteria exhibited an intermediate sensitivity to
the carbapenem selected), and in two of these cases the
carbapenem was associated with another active antibiotic
(AMK or FOF). In this scenario the inoculum effect is
probably an important variable that could explain the fa-
vorable outcome of our patients treated with carbapenems
[16], in whom the antibiotic treatment supplemented
the extraction of catheters and/or the drainage of col-
lections, adjunctive therapies which undoubtedly meant
a drastic reduction of the inoculum [19]. The probable
usefulness of continuous infusion regimens was not
tested in any of our patients [20].
Carbapenem resistance in K. pneumoniae is a growing
problem in the hospital setting that limits the use of this
antibiotic group for therapeutic purposes. There are
several families of enzymes that are responsible for this
increase in resistance, mainly KPC and VIM [1]. How-
ever, an increase in resistance to carbapenems due to
OXA-48 carbapenemase-producing clones has recently
been observed, especially associated with nosocomial
outbreaks in Mediterranean countries, the first of which
occurred in Turkey in 2004 [12].
This resistance determinant has now been detected
worldwide in several bacterial species such as Escherichia
coli, Enterobacter cloacae [21], and Citrobacter freundii
[4], although the predominant species are E. coli and K.
pneumoniae. In the present study we documented a clonal
outbreak due to K. pneumoniae producing CTX-M-15
and OXA-48 carbapenemase. The sequence type of the
epidemic strain (ST101) producing both enzymes (CTX-
M-15 and OXA-48) has also been detected in other
European and Mediterranean countries such as Israel and
Tunisia [2, 4, 22], suggesting a continental spread of this
multidrug-resistant lineage that has not yet been eradi-
cated [23]. The dissemination across Spain and Europe of
the OXA-48 enzyme has been described in several studies
[2, 24, 25]. The most prevalent K. pneumoniae clones are
ST101, ST11, and ST405, although in our hospital we
have only detected OXA-48 isolates with ST101. The
OXA-48 enzyme has been detected in various well-
described clones of K. pneumoniae: ST101, ST11,
ST14, ST15, ST147, ST395, and ST405 have already
been reported in European and Mediterranean coun-
tries [23–28].
Patients affected by CR-KP isolates in our hospital shared
certain characteristics with those of other outbreaks in our
geographic area [2, 24, 25]. They were patients with signifi-
cant comorbidities who had been exposed to major anti-
biotic pressure and whose infection was hospital-acquired.
These infections were related to previous surgery or other
invasive procedures (central venous catheters or urinary
catheters). Fourteen patients received carbapenems prior to
the CR-KP isolation. Although no case control studies have
been published, previous carbapenem therapy has been
identified in many studies describing CR-KP outbreaks
[29]. In fact, this risk factor was more frequently identi-
fied in patients with CR-KP isolates than in those with
CS-KP isolates.
The coproduction of ESBL with the blaOXA-48 gene is
frequent and mainly related to the presence of plasmids
[5]. In our study the co-existence of carbapenem-resistant
and susceptible strains could be explained by the presence
of the blaOXA-48 and blaCTX-M-15 genes in independent
elements. The transmissibility of the plasmid-encoded
blaOXA-48 favored the rapid spread of these strains, so the
acquisition of blaOXA-48 by the carbapenem-susceptible
strain could have occurred in our institution. The blaOXA-48
gene was detected located on a 62-kb IncL/M plasmid or
on a 70-kb plasmid, indicating that a plasmid of variable
size was mainly responsible for the spread of this gene
[4, 21].
Conclusions
Multi-resistant isolates of European carbapenem-resistant
OXA-48K. pneumoniae clone (ST101), previously identi-
fied in other Spanish hospitals and harboring plasmids
carrying the blaOXA-48 gene, have been producing an out-
break in our hospital in Barcelona (Spain). In conclusion,
the European carbapenem-resistant OXA-48K. pneumo-
niae clone (ST101) is spreading among Spanish hospitals.
Previous carbapenem use was identified as a common
factor in affected patients. These multidrug-resistant iso-
lates were successfully treated with tigecycline, colis-
tin, or carbapenems combined with other antibiotics
and adjunctive therapies. The spread of these strains
suggests a plausible scenario in which the acquisition
of new resistance determinants may make a strain
extremely drug-resistant. Thus, these results highlight
the need for surveillance of all multidrug-resistant K.
pneumoniae isolates, not only those that produce car-
bapenemase or ESBL.
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